PubRank

Stephen W Fesik

Author PubWeight™ 98.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005 22.40
2 Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A 2003 3.74
3 Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004 3.47
4 Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007 3.24
5 siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res 2005 3.21
6 Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 2012 3.09
7 Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 2005 2.67
8 Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem 2012 2.23
9 Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008 2.10
10 Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem 2007 2.09
11 Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004 2.05
12 Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 2008 1.85
13 Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res 2007 1.81
14 A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006 1.67
15 Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 2006 1.64
16 Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 2008 1.55
17 Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein. Biochemistry 2004 1.53
18 Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. J Biol Chem 2002 1.52
19 Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus. Proc Natl Acad Sci U S A 2002 1.52
20 Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005 1.49
21 Defining the optimal parameters for hairpin-based knockdown constructs. RNA 2007 1.48
22 The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 2010 1.47
23 ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 2008 1.34
24 Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem 2006 1.33
25 Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett 2004 1.33
26 A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A 2008 1.33
27 Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther 2007 1.31
28 Development of a tightly regulated U6 promoter for shRNA expression. FEBS Lett 2004 1.30
29 Solution structure of the BHRF1 protein from Epstein-Barr virus, a homolog of human Bcl-2. J Mol Biol 2003 1.26
30 Fragment-based drug discovery using NMR spectroscopy. J Biomol NMR 2013 1.17
31 Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am Chem Soc 2003 1.11
32 Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem Biol Drug Des 2007 1.08
33 Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc Natl Acad Sci U S A 2014 1.04
34 A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A. Anal Biochem 2011 1.03
35 Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett 2010 1.02
36 Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA. J Am Chem Soc 2003 1.02
37 Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res 2006 1.01
38 Discovery of a potent stapled helix peptide that binds to the 70N domain of replication protein A. J Med Chem 2014 0.97
39 Discovery of Protein-Protein Interaction Inhibitors of Replication Protein A. ACS Med Chem Lett 2013 0.95
40 Non-peptidic small molecule inhibitors of XIAP. Bioorg Med Chem Lett 2005 0.93
41 Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach. J Med Chem 2013 0.93
42 Fragment-based screening of the bromodomain of ATAD2. J Med Chem 2014 0.92
43 A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors. RNA 2011 0.89
44 Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization. Proc Natl Acad Sci U S A 2010 0.87
45 A strategy for high-throughput assay development using leads derived from nuclear magnetic resonance-based screening. J Biomol Screen 2002 0.86
46 Ligand binding to domain-3 of human serum albumin: a chemometric analysis. J Comput Aided Mol Des 2003 0.86
47 NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J Med Chem 2002 0.85
48 NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter. J Med Chem 2004 0.84
49 Surface reengineering of RPA70N enables cocrystallization with an inhibitor of the replication protein A interaction motif of ATR interacting protein. Biochemistry 2013 0.84
50 Developing lipid nanoparticle-based siRNA therapeutics for hepatocellular carcinoma using an integrated approach. Mol Cancer Ther 2013 0.79
51 A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand. J Biomol NMR 2014 0.78
52 1H, 13C and 15N resonance assignments of a Bcl-xL/Bad peptide complex. J Biomol NMR 2005 0.77
53 From bacterial genomes to novel antibacterial agents: discovery, characterization, and antibacterial activity of compounds that bind to HI0065 (YjeE) from Haemophilus influenzae. Chem Biol Drug Des 2007 0.77
54 Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide. Protein Expr Purif 2004 0.77
55 Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. J Med Chem 2003 0.75